Navidea Biopharmaceuticals has received a Small Business Innovation Research grant from the NIH's National Institute on Aging that will partially fund a Phase IIB clinical study of its NAV4694 beta-amyloid imaging agent. The agent is being evaluated for its potential in determining people with mild cognitive impairment that might lead to Alzheimer's disease.

Related Summaries